MarketCap
Facebook
X
Telegram
Epizyme Operating Income | EPZM
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -238 M | -225 M | -177 M | -128 M | -137 M | -112 M | -133 M | -55 M | -3.13 M | -768 K | -21 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -768 K | -238 M | -112 M |
Quarterly Operating Income Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -29.8 M | -50.9 M | - | -64.1 M | -58.2 M | -64.3 M | -62.1 M | -54.4 M | -57.6 M | -51.4 M | -57.5 M | -38 M | -50.7 M | -31 M | -24.3 M | -38.6 M | -30.3 M | -35 M | -37.4 M | -38.1 M | -28.5 M | -33 M | -35.5 M | -24.8 M | -28.4 M | -23.1 M | -22.3 M | -23.1 M | -25.8 M | -61.4 M | -15.1 M | -19.7 M | -13.3 M | -6.91 M | 16.3 M | -9.73 M | -2.18 M | -7.48 M | -4.54 M | 4.44 M | 4.8 M | -5.48 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.3 M | -64.3 M | -30.2 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
15.1 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-76.4 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
-108 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
-122 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
-52.7 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-96.6 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-77.5 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
191 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
-71.8 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
-385 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-98.4 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
-99.2 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
-4.34 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-52.1 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
-140 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
-39.5 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
-68.3 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
-68.3 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-51.5 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
-18.9 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
-209 M | - | - | $ 76.9 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-117 M | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
-121 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
-185 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
-87.7 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
-92.9 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
-495 M | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
-22.7 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
21.8 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-39 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
-36.6 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-2.04 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-46.3 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
-760 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
-33 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
-42 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-10.6 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-4.28 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
-54.5 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
-76.5 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-37 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-41.7 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
5.16 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-127 M | - | 1.02 % | $ 90.8 M | Britain |